Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest- Additional Information (Detail)

v3.5.0.2
Debt and Interest- Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2016
Feb. 29, 2016
Feb. 13, 2014
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Mar. 31, 2015
Mar. 17, 2014
Debt [Line Items]                    
Fees related to the loan agreement           $ 249,000 $ 0      
Notes Payable $ 14,000,000     $ 14,000,000   $ 14,000,000        
Sale of Stock, Percentage of Ownership after Transaction           12.00%        
Repayments of Debt   $ 2,800,000                
Equity Method Investment, Ownership Percentage                   35.00%
Helocyte Inc [Member]                    
Debt [Line Items]                    
Class of Warrant or Right, Warrants Term 5 years                  
Letter of Credit [Member]                    
Debt [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage 2.00%     2.00%   2.00%        
Letters of Credit Outstanding, Amount $ 1,700,000     $ 1,700,000   $ 1,700,000        
Israel Discount Bank Of New York [Member]                    
Debt [Line Items]                    
Debt Instrument, Face Amount     $ 15,000,000              
Notes Payable $ 14,000,000     $ 14,000,000   $ 14,000,000        
IDB Promissory Note Payable [Member]                    
Debt [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage 2.25%     2.25%   2.25%        
Debt Instrument, Face Amount     15,000,000              
IDB Promissory Note Payable [Member] | Minimum [Member]                    
Debt [Line Items]                    
Debt Instrument, Unused Borrowing Capacity, Amount     100,000              
NSC Note [Member]                    
Debt [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage 8.00%     8.00%   8.00%        
Debt Instrument, Fee Amount               $ 900,000    
Notes Payable                 $ 10,000,000  
Debt Instrument, Interest Rate, Effective Percentage               12.40%    
NSC Note [Member] | Warrant [Member]                    
Debt [Line Items]                    
Debt Instrument, Unamortized Discount (Premium), Net, Total $ 113,500     $ 113,500   $ 113,500        
Long-term Debt, Fair Value   174,000                
Hercules Note Payble [Member]                    
Debt [Line Items]                    
Fees related to the loan agreement       $ 249,000 $ 0 $ 249,000 $ 0      
Debt Instrument, Periodic Payment, Interest     100,000              
Debt Instrument, Periodic Payment     $ 14,000,000              
National Holding’s Corporation Inc [Member] | Board of Directors Chairman [Member]                    
Debt [Line Items]                    
Equity Method Investment, Ownership Percentage 4.20%     4.20%   4.20%        
Helocyte Convertible Note [Member]                    
Debt [Line Items]                    
Debt Instrument, Term           18 months        
Proceeds from Issuance or Sale of Equity           $ 10,000,000        
Sale of Stock, Consideration Received on Transaction           875,000        
Legal Fees           25,000        
Class of Warrant or Right, Value of Securities Called by Warrants or Rights           $ 100,000        
Class of Warrant or Right, Exercise Price Percentage of Warrants or Rights           110.00%        
Helocyte Convertible Note [Member] | Conversion One [Member]                    
Debt [Line Items]                    
Debt Instrument, Convertible, Terms of Conversion Feature (a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.                  
Helocyte Convertible Note [Member] | Conversion Two [Member]                    
Debt [Line Items]                    
Debt Instrument, Convertible, Terms of Conversion Feature (a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).                  
Helocyte Convertible Note [Member] | Minimum [Member]                    
Debt [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage 5.00%     5.00%   5.00%        
Helocyte Convertible Note [Member] | Maximum [Member]                    
Debt [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage 8.00%     8.00%   8.00%        
Debt Instrument, Face Amount $ 5,000,000     $ 5,000,000   $ 5,000,000        
NSC [Member]                    
Debt [Line Items]                    
Debt Instrument, Term           10 years        
Checkpoint [Member]                    
Debt [Line Items]                    
Debt Instrument, Unamortized Discount (Premium), Net, Total   $ 324,000                
Checkpoint [Member] | NSC Note [Member]                    
Debt [Line Items]                    
Fees related to the loan agreement           $ 2,800,000        
Avenue [Member]                    
Debt [Line Items]                    
Debt Instrument, Unamortized Discount (Premium), Net, Total $ 237,000     $ 237,000   237,000        
Avenue [Member] | NSC Note [Member]                    
Debt [Line Items]                    
Fees related to the loan agreement           $ 3,000,000